Although the mutation and activation of EGFR are recognized as important oncogenic drivers in NSCLC patients, targeting EGFR using currently existing EGFR-TKIs has shown limited success due to the emergence of acquired resistance34. This evidence concerns the gene EGFR and non-small cell lung carcinoma.